Chargement en cours...
Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
Background: Immune checkpoint blockade has revolutionized the treatment of multiple malignancies. Currently, however, the effect is not universal, with objective response rates (ORR) of about 15–25%, and even lower for some cancers. Abnormal vasculature is a hallmark of most solid tumors and plays a...
Enregistré dans:
| Publié dans: | Front Pharmacol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Frontiers Media S.A.
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6812341/ https://ncbi.nlm.nih.gov/pubmed/31680957 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.01173 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|